{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T12:56:50Z","timestamp":1790600210867,"version":"4.1.0"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:p>The concept of a \u201cmagic bullet\u201d in oncology\u2014first envisioned by Paul Ehrlich\u2014has evolved into one of the most dynamic areas in precision cancer therapeutics: antibody\u2013drug conjugates (ADCs). These biopharmaceuticals combine the selectivity of monoclonal antibodies with the potency of cytotoxic agents through specialized linkers, achieving targeted delivery of chemotherapeutic compounds to malignant cells while minimizing systemic toxicity. This narrative review explores the molecular foundations, pharmacologic mechanisms, and clinical evolution of ADCs, emphasizing their transformative impact on breast cancer management. ADCs are structured around three essential components: an antibody that binds a tumor-specific antigen, a linker that ensures controlled payload release, and a cytotoxic drug that induces apoptosis once internalized. The interaction of the ADC\u2013antigen complex leads to endocytosis, lysosomal degradation, and payload liberation. Depending on the properties of the linker and the permeability of the cytotoxic payload, the cytotoxic effect can extend to neighboring cells\u2014a phenomenon termed the bystander effect. Advances in linker chemistry, such as the use of acid-labile, enzyme-labile, or disulfide-cleavable bonds, together with the humanization of antibody backbones, have significantly improved pharmacokinetics, stability, and safety. The evolution of ADC generations illustrates progressive refinements in bioengineering and therapeutic efficacy. First-generation ADCs, such as Gemtuzumab ozogamicin, demonstrated the proof of concept but suffered from high immunogenicity, poor selectivity, and heterogeneous drug\u2013antibody ratios. Second-generation ADCs introduced stable linkers and humanized antibodies, exemplified by Ado-trastuzumab emtansine (T-DM1), which targets the HER2 receptor in breast cancer. Clinical trials such as EMILIA and HER2CLIMB-02 confirmed improved survival outcomes and reduced toxicity compared with conventional chemotherapy. Third-generation ADCs, including Trastuzumab deruxtecan and Sacituzumab govitecan, incorporate site-specific conjugation, higher drug-to-antibody ratios, and potent payloads capable of inducing bystander killing even in tumors with low antigen expression. Landmark studies such as DESTINY-Breast03, DESTINY-Breast04, DESTINY-Breast06, ASCENT, and TROPiCS-02 have positioned these agents as pivotal therapies across HER2-positive, HER2-low, and triple-negative breast cancer subtypes. Despite these advances, resistance mechanisms remain a significant challenge. These include antigen downregulation, overexpression of efflux pumps, impaired intracellular trafficking, and reduced payload activation. Nevertheless, the modular architecture of ADCs allows iterative optimization of their antibody, linker, and payload components to overcome these barriers. Future developments are exploring bispecific ADCs that target multiple antigens, radiolabeled or immune-activating conjugates, and masked ADCs engineered for selective activation within tumor microenvironments, all of which aim to further refine selectivity, potency, and therapeutic benefit.<\/jats:p>\n                  <jats:p>In conclusion, ADCs exemplify the convergence of molecular biology, immunology, and medicinal chemistry in the pursuit of precision oncology. Their progressive evolution from concept to clinic not only validates Ehrlich\u2019s century-old vision but also heralds a new therapeutic era in which cancer treatment achieves unprecedented specificity, efficacy, and improvement in patient outcomes.<\/jats:p>","DOI":"10.4103\/hemoncstem.hemoncstem-d-24-00042","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T06:00:08Z","timestamp":1770098408000},"page":"133-139","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Antibody-Drug Conjugates (ADCs) for Breast Cancer Therapeutic Landscape: Concept and Mechanisms of Action"],"prefix":"10.4103","volume":"18","author":[{"given":"Roberto","family":"Paz-Manrique","sequence":"first","affiliation":[{"name":"Carrera de Medicina Humana, Facultad de Ciencias de la Salud, Universidad San Ignacio de Loyola, Lima, Peru"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Pinto","sequence":"additional","affiliation":[{"name":"Unidad de Investigacion Basica y Traslacional, AUNA Ideas, Lima, Peru"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry L.","family":"Gomez Moreno","sequence":"additional","affiliation":[{"name":"Breast Cancer Group AUNA Health System, AUNA Oncosalud, Lima, Peru"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"key":"R1-20260708","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrc2394","article-title":"Paul Ehrlich\u2019s magic bullet concept: 100 years of progress","volume":"8","author":"Strebhardt","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"R2-20260708","doi-asserted-by":"crossref","first-page":"518","DOI":"10.3390\/jpm11060518","article-title":"Precision medicine in oncology: a review of multi-tumor actionable molecular targets with an emphasis on non-small cell lung cancer","volume":"11","author":"Stein","year":"2021","journal-title":"J Pers Med"},{"key":"R3-20260708","doi-asserted-by":"crossref","first-page":"8643","DOI":"10.1158\/0008-5472.CAN-07-6611","article-title":"A history of cancer chemotherapy","volume":"68","author":"DeVita","year":"2008","journal-title":"Cancer Res"},{"key":"R4-20260708","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1038\/s12276-022-00864-3","article-title":"Molecular targeted therapy for anticancer treatment","volume":"54","author":"Min","year":"2022","journal-title":"Exp Mol Med"},{"key":"R5-20260708","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.3747\/co.27.5223","article-title":"A review of cancer immunotherapy: from the past, to the present, to the future","volume":"27","author":"Esfahani","year":"2020","journal-title":"Curr Oncol"},{"key":"R6-20260708","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1541-7786.MCR-19-0582","article-title":"Antibody-drug conjugates: a comprehensive review","volume":"18","author":"Khongorzul","year":"2020","journal-title":"Molecular Cancer Res"},{"key":"R7-20260708","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1007\/s11095-015-1624-3","article-title":"Evolving strategies for target selection for antibody-drug conjugates","volume":"32","author":"Damelin","year":"2015","journal-title":"Pharm Res"},{"key":"R8-20260708","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3390\/pharmaceutics14020396","article-title":"Linkers: an assurance for controlled delivery of antibody-drug conjugate","volume":"14","author":"Sheyi","year":"2022","journal-title":"Pharmaceutics"},{"key":"R9-20260708","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1111\/iju.14925","article-title":"Current status and future prospects of antibody-drug conjugates in urological malignancies","volume":"29","author":"Hayashi","year":"2022","journal-title":"Int J Urol"},{"key":"R10-20260708","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1021\/ar700108g","article-title":"Targeted cancer therapy: conferring specificity to cytotoxic drugs","volume":"41","author":"Chari","year":"2008","journal-title":"Acc Chem Res"},{"key":"R11-20260708","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1007\/s11095-015-1657-7","article-title":"Current ADC linker chemistry","volume":"32","author":"Jain","year":"2015","journal-title":"Pharm Res"},{"key":"R12-20260708","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.3390\/biomedicines11113080","article-title":"Lysosomal-cleavable peptide linkers in antibody-drug conjugates","volume":"11","author":"Balamkundu","year":"2023","journal-title":"Biomedicines"},{"key":"R13-20260708","doi-asserted-by":"crossref","first-page":"114624","DOI":"10.1016\/j.addr.2022.114624","article-title":"Lysosomal-mediated drug release and activation for cancer therapy and immunotherapy","volume":"192","author":"Sun","year":"2023","journal-title":"Adv Drug Deliv Rev"},{"key":"R14-20260708","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s11912-022-01266-4","article-title":"Bystander effect of antibody-drug conjugates: fact or fiction?","volume":"24","author":"Giugliano","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"R15-20260708","first-page":"4154","article-title":"Phase I clinical comparative study of monoclonal antibody KS1\/4 and KS1\/4-methotrexate immunconjugate in patients with non-small cell lung carcinoma","volume":"50","author":"Elias","year":"1990","journal-title":"Cancer Res"},{"key":"R16-20260708","first-page":"35","article-title":"Antibody-drug conjugates as novel anti-cancer chemotherapeutics","author":"Peters","year":"2015","journal-title":"Biosci Rep"},{"key":"R17-20260708","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/17512433.2018.1478725","article-title":"Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia","volume":"11","author":"Baron","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R18-20260708","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s40265-013-0050-2","article-title":"Trastuzumab emtansine: first global approval","volume":"73","author":"Ballantyne","year":"2013","journal-title":"Drugs"},{"key":"R19-20260708","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s40164-022-00347-1","article-title":"Learn from antibody-drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy","volume":"11","author":"Wu","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"R20-20260708","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1080\/19420862.2019.1624127","article-title":"Site-specific antibody-drug conjugate heterogeneity characterization and heterogeneity root cause analysis","volume":"11","author":"Cao","year":"2019","journal-title":"MAbs"},{"key":"R21-20260708","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0169-409X(97)00095-1","article-title":"Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy","volume":"31","author":"Chari RVJ","year":"1998","journal-title":"Adv Drug Deliv Rev"},{"key":"R22-20260708","first-page":"14","article-title":"The role of tumor-associated antigen HER2\/neu in tumor development and the different approaches for using it in treatment: many choices and future directions","author":"Alrhmoun","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R23-20260708","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1093\/annonc\/12.suppl_1.S23","article-title":"HER2 as a prognostic and predictive marker for breast cancer","volume":"12","author":"Cooke","year":"2001","journal-title":"Ann Oncol"},{"key":"R24-20260708","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10549-010-1090-x","article-title":"Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer","volume":"128","author":"Junttila","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"R25-20260708","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3390\/molecules22020297","article-title":"Adamantane in drug delivery systems and surface recognition","volume":"22","author":"\u0160timac","year":"2017","journal-title":"Molecules"},{"key":"R26-20260708","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"key":"R27-20260708","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS20-OT-28-01","article-title":"Abstract OT-28-01: HER2CLIMB-02: a randomized, double-blind, phase 3 study of tucatinib or placebo with T-DM1 for unresectable locally-advanced or metastatic HER2+ breast cancer","volume":"81","author":"Hurvitz","year":"2021","journal-title":"Cancer Res"},{"key":"R28-20260708","first-page":"9","article-title":"Advances and limitations of antibody drug conjugates for cancer","author":"Mckertish","year":"2021","journal-title":"Biomedicines"},{"key":"R29-20260708","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s10930-024-10201-4","article-title":"Understanding the specific implications of amino acids in the antibody development","volume":"43","author":"Gavade","year":"2024","journal-title":"Protein J"},{"key":"R30-20260708","first-page":"151","article-title":"Profile of trastuzumab deruxtecan in the management of patients with HER2-positive unresectable or metastatic breast cancer: an evidence-based review","volume":"13","author":"Linehan","year":"2021","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"R31-20260708","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/bdd.2371","article-title":"Transition of average drug\u2010to\u2010antibody ratio of trastuzumab deruxtecan in systemic circulation in monkeys using a hybrid affinity capture liquid chromatography\u2010tandem mass spectrometry","volume":"44","author":"Habara","year":"2023","journal-title":"Biopharm Drug Dispos"},{"key":"R32-20260708","doi-asserted-by":"crossref","first-page":"9674","DOI":"10.3390\/ijms24119674","article-title":"Mechanisms of resistance to antibody-drug conjugates","volume":"24","author":"Khoury","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R33-20260708","doi-asserted-by":"crossref","first-page":"S335","DOI":"10.1016\/j.annonc.2023.09.554","article-title":"377O A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB) \u221201, \u221202, and \u221203","volume":"34","author":"Hurvitz","year":"2023","journal-title":"Ann Oncol"},{"key":"R34-20260708","doi-asserted-by":"crossref","first-page":"LBA1000","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA1000","article-title":"Trastuzumab deruxtecan (T-DXd) vs physician\u2019s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06)","volume":"42","author":"Curigliano","year":"2024","journal-title":"J Clin Oncol"},{"key":"R35-20260708","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"R36-20260708","doi-asserted-by":"crossref","first-page":"11513","DOI":"10.1074\/jbc.RA119.008084","article-title":"Trophoblast cell surface antigen 2 (Trop-2) phosphorylation by protein kinase C \u03b1\/\u03b4 (PKC\u03b1\/\u03b4) enhances cell motility","volume":"294","author":"Mori","year":"2019","journal-title":"J Biol Chem"},{"key":"R37-20260708","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.21037\/atm-22-5976","article-title":"A literature review of the promising future of TRO P2: a potential drug therapy target","volume":"10","author":"Wen","year":"2022","journal-title":"Ann Transl Med"},{"key":"R38-20260708","doi-asserted-by":"crossref","first-page":"100497","DOI":"10.1016\/j.esmoop.2022.100497","article-title":"The European Medicines Agency review of sacituzumab govitecan for the treatment of triple-negative breast cancer","volume":"7","author":"Michaleas","year":"2022","journal-title":"ESMO Open"},{"key":"R39-20260708","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"key":"R40-20260708","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"key":"R41-20260708","doi-asserted-by":"crossref","first-page":"TPS1102","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS1102","article-title":"Saci-IO HR+: randomized phase II trial of sacituzumab govitecan (SG) +\/\u2212 pembrolizumab in PD-L1+ hormone receptor-positive (HR+) \/ HER2- metastatic breast cancer (MBC)","volume":"39","author":"Garrido-Castro","year":"2021","journal-title":"J Clin Oncol"},{"key":"R42-20260708","doi-asserted-by":"crossref","first-page":"114408","DOI":"10.1016\/j.biopha.2023.114408","article-title":"A comprehensive review of key factors affecting the efficacy of antibody drug conjugate","volume":"161","author":"Samantasinghar","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"R43-20260708","first-page":"15","article-title":"Target antigen attributes and their contributions to clinically approved antibody-drug conjugates (ADCs) in haematopoietic and solid cancers","author":"Esapa","year":"2023","journal-title":"Cancers (Basel"},{"key":"R44-20260708","first-page":"3","article-title":"Antibody-drug conjugates: possibilities and challenges","volume":"11","author":"Nejadmoghaddam","year":"2019","journal-title":"Avicenna J Med Biotechnol"},{"key":"R45-20260708","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s12272-023-01433-6","article-title":"Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry","volume":"46","author":"Hong","year":"2023","journal-title":"Arch Pharm Res"},{"key":"R46-20260708","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1038\/s41467-021-23793-7","article-title":"Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance","volume":"12","author":"Yamazaki","year":"2021","journal-title":"Nat Commun"},{"key":"R47-20260708","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cllc.2022.11.004","article-title":"Amivantamab, an epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET) bispecific antibody, designed to enable multiple mechanisms of action and broad clinical applications","volume":"24","author":"Cho","year":"2023","journal-title":"Clin Lung Cancer"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/hemoncstem.HEMONCSTEM-D-24-00042","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:27:32Z","timestamp":1786735652000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/hemoncstem.HEMONCSTEM-D-24-00042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/hemoncstem.hemoncstem-d-24-00042","relation":{},"ISSN":["1658-3876","2589-0646"],"issn-type":[{"value":"1658-3876","type":"print"},{"value":"2589-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"2024-10-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}